Pam Cheng - AstraZeneca PLC President

AZN Stock  USD 67.75  0.51  0.75%   

President

Ms. Pam P. Cheng is Executive Vice President Operations and Information Technology of the Company. She joined AstraZeneca in June 2015 after having spent 18 years with MerckMSD in Global Manufacturing and Supply Chain and Commercial roles. Pam was the Head of Global Supply Chain Management Logistics for Merck from 2006 to 2011 and led the transformation of Merck supply chains across the global supply network. More recently, Pam was President of MSD China, responsible for MSDs entire business in China. Prior to joining Merck, Pam held various engineering and project management positions at Universal Oil Products, Union Carbide Corporation and GAF Chemicals. Pam holds Bachelors and Masters degrees in chemical engineering from Stevens Institute of Technology in New Jersey and an MBA in marketing from Pace University in New York. In addition to her role at AstraZeneca, Pam serves as a nonexecutive Director of the Codexis Inc. Board . Pam also serves as an Advisor to the International Society of Pharmaceutical Engineering Board of Directors. since 2015.
Age 54
Tenure 9 years
Professional MarksMBA
Address 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
Phone44 20 3749 5000
Webhttps://www.astrazeneca.com

AstraZeneca PLC Management Efficiency

The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2024, Return On Assets is likely to grow to 0.10, while Return On Capital Employed is likely to drop 0.11. At this time, AstraZeneca PLC's Asset Turnover is very stable compared to the past year.
The company has 28.62 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

William ColtonExxon Mobil Corp
62
Theodore WojnarExxon Mobil Corp
60
Catherine HoovelMcDonalds
53
Pierre BreberChevron Corp
60
Kenneth KoziolMcDonalds
54
Jacqueline CanneyWalmart
50
M BiggsWalmart
51
Bea PerezThe Coca Cola
N/A
Kate RamundoAlcoa Corp
48
Alan KellyExxon Mobil Corp
57
Erich ClementiInternational Business Machines
58
Robert LeBlancInternational Business Machines
56
Terry LaughlinBank Of America
56
Robert GibbsMcDonalds
48
David ChojnowskiWalmart
50
D WascomExxon Mobil Corp
59
Bernhard GoepeltThe Coca Cola
55
Claudia LorenzoThe Coca Cola
N/A
Jeffrey GearhartWalmart
51
Sara OrtweinExxon Mobil Corp
59
James DinkinsThe Coca Cola
56
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 83100 people. AstraZeneca PLC ADR (AZN) is traded on NASDAQ Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA and employs 89,900 people. AstraZeneca PLC is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

AstraZeneca PLC ADR Leadership Team

Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, Chief Financial Officer, Executive Director
Sherilyn McCoy, Non-Executive Independent Director
Genevieve Berger, Non-Executive Independent Director
Luke Miels, Executive Vice-President GPPS
Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development
Paul Hudson, Executive Vice President North America
Nazneen Rahman, Non-Executive Independent Director
Jose Baselga, Executive Vice President - Research & Development Oncology
JeanPhilippe Courtois, Non-Executive Independent Director
Deborah Eldracher, Non-Executive Independent Director
Thomas Larsen, IR Contact Officer
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer
Tony Mok, Non-Executive Independent Director
Mark Mallon, Executive Vice President International
Fiona Cicconi, Executive Vice President - Human Resources
Deborah DiSanzo, Non-Executive Independent Director
Chris Sheldon, Head Relations
Shriti Vadera, Non-Executive Independent Director
Leif Johansson, Non-Executive Independent Chairman of the Board
Leon Wang, Executive Vice President - International and China President
Ann Cairns, Non-Executive Director
Adrian Kemp, Company Secretary
Cornelia Bargmann, Non-Executive Director
Susan MD, Executive Development
Tim JacksonSmith, Non-Executive Director
Michel Demare, Non-Executive Independent Director
Graham Chipchase, Senior Non-Executive Independent Director
David Smith, Executive VP of Operations and Information Services
Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee
Pam Cheng, Executive Vice-President of Operations and Information Technology
Baroness Vadera, Non-Executive Independent Director
MBA DVM, CEO Director
Aradhana MD, CFO Director
Philip Broadley, Non-Executive Independent Director
Narayan Seshadri, Independent Director
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business
David Fredrickson, Executive Vice-President Global Head Oncology Business Unit
Gonzalo Vina, Head Relations
Andrew Barnett, Head Relations
Bahija Jallal, Executive Vice President MedImmune
Rudolph Markham, Non-Executive Independent Director
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals
Weiying Wang, Non-Executive Director
Bruce Burlington, Non-Executive Independent Director
Marcus Wallenberg, Non-Executive Director
Iskra Reic, Executive Vice President - Europe and Canada

AstraZeneca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

AstraZeneca PLC Investors Sentiment

The influence of AstraZeneca PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in AstraZeneca. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to AstraZeneca PLC's public news can be used to forecast risks associated with an investment in AstraZeneca. The trend in average sentiment can be used to explain how an investor holding AstraZeneca can time the market purely based on public headlines and social activities around AstraZeneca PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
AstraZeneca PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for AstraZeneca PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average AstraZeneca PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on AstraZeneca PLC.

AstraZeneca PLC Implied Volatility

    
  21.4  
AstraZeneca PLC's implied volatility exposes the market's sentiment of AstraZeneca PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if AstraZeneca PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that AstraZeneca PLC stock will not fluctuate a lot when AstraZeneca PLC's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AstraZeneca PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AstraZeneca PLC's short interest history, or implied volatility extrapolated from AstraZeneca PLC options trading.

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving against AstraZeneca Stock

  0.48MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for AstraZeneca Stock analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
CEOs Directory
Screen CEOs from public companies around the world
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.059
Dividend Share
2.9
Earnings Share
1.9
Revenue Per Share
2.4547
Quarterly Revenue Growth
0.073
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.